The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-03), Procyon's 14-Day RSI is 21.73.
The industry rank for Procyon's 14-Day RSI or its related term are showing as below:
PCYN's 14-Day RSI is not ranked
in the Drug Manufacturers industry.
Industry Median: 49.14
vs PCYN: 21.73
Procyon (OTCPK:PCYN) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Procyon 14-Day RSI Related Terms
PCYN vs KAYS, YCBD, CBDY: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procyon 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procyon's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Procyon's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procyon (PCYN) has a 14-Day RSI of 21.73 as of Jul. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Procyon and its competitors.
Is Procyon's 14-Day RSI too high?
Procyon's current 14-Day RSI is 21.73. The Drug Manufacturers industry median 14-Day RSI is 49.14. Procyon's value of 21.73 is 55.8% below this industry median. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's 14-Day RSI compare to KAYS and YCBD?
Procyon's 14-Day RSI of 21.73 can be compared against companies in the Drug Manufacturers industry. The industry median 14-Day RSI is 49.14. Procyon's value of 21.73 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 49.14, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procyon's current 14-Day RSI of 21.73 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Procyon and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 49.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procyon's current 14-Day RSI is 21.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current 14-Day RSI of 21.73. The current 14-Day RSI is 21.73 and 55.8% below the Drug Manufacturers industry median of 49.14. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Procyon (PCYN), the current 14-Day RSI is 21.73 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score
Get the complete analysis for PCYN
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCYN has been successfully added to your 